Eli Lilly, one of the world’s biggest pharmaceutical companies, is reportedly preparing a €15 billion offer to acquire the French biotechnology firm Abivax SA, according to recent market reports. This potential deal reflects a strategic push by Eli Lilly to expand its presence in the biotech sector, tapping into cutting‑edge research and development pipelines that…
We examine how Eli Lilly & Co. (commonly referred to as Eli Lilly) has taken a major decision by pulling its employees out of CVS Health Corp.’s pharmacy benefit plan. The move follows CVS’s choice to de-prioritise Lilly’s weight-loss drug. This story touches on drug pricing, corporate strategy, and the wider implications for the stock…
Eli Lilly stock caught eyes today. It rose 3.36% during the day. This happened on August 16, 2025. The close was at 699.815. That marked a 2.47% gain overall. Traders saw 6,231,151 shares change hands. No big news drove this move. Peers in biotech and pharma showed mixed results. Some fell while others climbed. Why…
We see Eli Lilly making waves with its bold decision to raise its 2025 sales guidance to $60 billion to $62 billion. This comes after a stellar second quarter, where revenue hit $15.56 billion, thanks to soaring sales of Mounjaro and Zepbound. For the stock market, this signals a bright future, though not without some…